PUBH 6331 Week 7 Peer Critique Example

Global Health and Social Justice Walden University Free custom sample in 24 to 48h

This PUBH 6331 Week 7 peer critique example presses a classmate who wrote that a lakeside community that hosted a trial of a long-acting HIV prevention injection is owed the drug afterward. Walden PUBH 6331 asks students to test classmates' claims of obligation, and the reply asks who owes and under which rule, checking four sources in turn. The current Declaration of Helsinki covers participants who still need a beneficial intervention, not the whole village; international research guidelines ask every effort toward availability for the host community, shared by sponsors and governments; a national rule or contract would be the strongest; reciprocity alone names no duty holder. The follow-up uses the classmate's finding that the plan ended after two years. For MPH students, the critique shows how to strengthen an argument rather than dismiss it.

CoursePUBH 6331 Global Health and Social Justice
WeekWeek 7
Paper typePeer critique reply
LengthAbout 650 words, 4 pages
FormatDiscussion reply, APA 7 citations
SchoolWalden University
ProgramMaster of Public Health (MPH)
UpdatedOctober 2026

Free sample paper for PUBH 6331 Week 7

1

Week 7 Discussion: Peer Critique on Post-Trial Obligations

Owed by Whom, Under Which Rule? A Peer Critique Pressing a Classmate to Name the Source of the Claim That a Lakeside Community Hosting an HIV Prevention Trial Is Owed the Drug Afterward

Reply to Leila

Leila, your post about the fishing community on the lake where a long-acting HIV prevention injection was tested moved me, and I think your conclusion may well be right. You wrote that "the community that hosted the trial is owed the drug afterward," and that the company should "give back what it took." I want to press on one thing: where does that obligation come from? I can think of four possible sources, and they lead to different duty holders and different scopes.

Source 1: The International Declaration

The current Declaration of Helsinki says that before a clinical trial, sponsors and researchers must arrange post-trial provisions, delivered by themselves, health systems or governments, for all participants who still need an intervention found beneficial and reasonably safe in the trial, and that participants must be told about these arrangements during consent (World Medical Association, 2025). That is a real obligation, but notice its reach: it covers participants, not the whole community. The 800 trial participants in your example would have a claim. The rest of the village would not, at least not under this text.

What this page is doingQuoting the declaration's scope precisely shows the classmate where the argument is strong and where it overreaches.
2

Source 2: International Research Guidelines

International research guidelines go further (Council for International Organizations of Medical Sciences, 2016) for research in low-resource settings. They ask sponsors, researchers and government authorities to make every effort to ensure that any intervention or product developed through the research is made available to the population or community where the research was done, as soon as possible. This is the closest support for your claim, and I think you should cite it. Its wording, however, is "every effort," and it names governments alongside sponsors, so it does not put the full duty on the company.

Source 3: National Regulation or Contract

Some host countries require a post-trial access plan as a condition of approving a trial, and some trial agreements include commitments to the community. If your country of interest has such a rule, or the sponsor signed such a commitment, that would be the strongest source of all, because it would be enforceable. Do you know whether the trial protocol or the national regulator required one?

Source 4: Conviction

Your phrase "give back what it took" points to reciprocity: the community bore risks and burdens, so it is owed a share of the benefit. That is a serious moral argument, and others have argued that post-trial responsibilities extend beyond simply continuing a drug, to things like sharing results with the community and strengthening local health care (Cho et al., 2018). But reciprocity on its own does not specify who owes what. Without one of the sources above, a company can agree with the principle and still say the duty belongs to the government.

My suggestion is to restate your claim in two parts: participants are owed continued access under the declaration, and the wider community has a claim to reasonable availability under the international guidelines, shared by the sponsor and the government. Would that still capture what you meant?

Follow-Up After Leila's Response

Thanks, Leila. You found that the national ethics committee did require a post-trial access plan, but only for participants, and that the plan ended after two years. That helps. It means the participants' claim rests on both the declaration and a national requirement, while the community's claim rests mainly on international research guidance, which is not binding law. I think your paper is stronger for saying so plainly. You might argue that the government, which approved the trial, has its own duty to seek community availability when it negotiates with sponsors. That moves the argument from what the company should feel to what the government could require next time.

References

Cho, H. L., Danis, M., & Grady, C. (2018). Post-trial responsibilities beyond post-trial access. The Lancet, 391(10129), 1478-1479. https://doi.org/10.1016/S0140-6736(18)30761-X

Council for International Organizations of Medical Sciences. (2016). International ethical guidelines for health-related research involving humans (4th ed.). https://cioms.ch/publications/product/international-ethical-guidelines-for-health-related-research-involving-humans/

World Medical Association. (2025). World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human participants. JAMA, 333(1), 71-74. https://doi.org/10.1001/jama.2024.21972

PUBH 6331 Week 7 instructions, in plain terms

Peer critique discussions ask students to evaluate a classmate's argument and suggest how to strengthen it. In a justice course, prompts often focus on whether a claim of obligation is supported by a standard and whether the right duty holder is named. Expect to write a few hundred words backed by a source or two, then answer the classmate again later in the week. Instructors value critiques that take the classmate's conclusion seriously, identify the specific weakness, offer options and remain respectful. A reply that simply agrees, or one that rejects the argument without suggesting a way forward, usually earns limited credit. Engagement with the classmate's response is often graded separately. Some sections also require that the critique propose at least one additional source the classmate could read.

How the PUBH 6331 Week 7 example is put together

The reply opens by stating the classmate's claim in her own words and saying what is promising about it. It then lists four possible sources of the obligation, each under its own heading: the declaration, international guidelines, national regulation or contract, and conviction. For each, it explains what the source says, who it binds and how far it reaches. A suggested restatement divides the claim into participants' and community's entitlements. The reply ends with a question. The follow-up uses the classmate's new information about the national requirement and suggests reframing the argument toward what governments could require. Each source heading lets the classmate jump to the part that applies to her.

Where the marks sit in the PUBH 6331 Week 7 rubric

Peer critiques are graded on accuracy, constructiveness and engagement. Accuracy matters because critiques of obligation depend on reporting standards correctly, such as the current scope of post-trial provisions. Constructiveness is shown by options the classmate can use, such as a restated claim or a new source. Engagement is judged in the follow-up, which should respond to what the classmate actually said. Tone and courtesy are part of the grade. Use of current versions of guidelines earns credit, as does citing scholarly work on the issue. Replies that rely on general praise or criticism without specific sources typically lose points. Critiques that suggest a restated version of the classmate's claim give the classmate something to use immediately.

Common PUBH 6331 Week 7 mistakes, and how to avoid them

The usual problem is a critique that says a claim "needs more support" without saying what support would help. Identify the exact sentence that makes the claim and list the possible sources of authority for it. Check current versions of ethical guidelines, since they change. Be clear about who each source binds. Suggest a restatement the classmate could use. Keep the tone collegial. In the follow-up, build on what the classmate found. We can write critiques of the classmate posts in your discussion board when you send them. Quote the classmate's exact words before critiquing them, and close with a question rather than a verdict. Use the current version of any declaration you cite, since older versions differ.

Get a PUBH 6331 Week 7 example written to your instructions

Copy the post you are answering, plus the Week 7 prompt and rubric, and the first critique, free, comes back in 24-48h. One sentence of that post is quoted for accuracy, the reply addresses reasoning, not the person, and nothing else of the classmate's writing is reused.

More PUBH 6331 papers and MPH samples

PUBH 6331 Week 7 questions, answered

Where can I find a free PUBH 6331 Week 7 sample paper?

The Week 7 critique and its follow-up are available above, examining a claim about post-trial access after an HIV prevention trial.

What does the Declaration of Helsinki say about post-trial access?

Sponsors and researchers must arrange in advance for participants who still need an intervention found beneficial and reasonably safe.

Are host communities owed access to trial drugs?

International research guidelines ask every effort to make products available to the host population, shared by sponsors and governments.

What is the strongest source of a post-trial obligation?

A national regulation or contract requiring it, because those can be enforced.

Why is reciprocity alone not enough?

It supports a moral claim but does not specify who owes what, letting each party point to another.